ID 原文 译文
1187 ECMO合并机械通气的撤离 Weaning from ECMO and Mechanical Ventilation
1188 1)V-V ECMO合并机械通气的患者,如果符合清醒ECMO条件,建议首先尝试撤除人工气道,除非已合并ECMO相关并发症,或者预期撤除所有机械辅助时间<48h。 (1) If a patient treated by V-V ECMO combined with mechanical ventilation satisfies the awake ECMO condition, we suggest to first tr y to remove the artificial air way, unless the patient has ECMO related complications, or the expected time of removal of all the assisting machines is less than 48 h.
1189 2)对于气道分泌物过多,需要频繁辅助人工吸引清除,且预计采用长时间机械通气的患者,符合PaO2/FiO2>150mmHg时间>48h,肺部影像表现好转稳定,机械通气压力相关损伤已经控制,可以首先撤除ECMO辅助,不建议保留ECMO插管。 (2) For a patient who has too much air way secretions that frequent artificial suction clearance is needed, who is expected to have a long-term mechanical ventilation support , who satisfies the conditions PaO2/FiO2 > 15 0 mmHg and time > 4 8 h, whose lung image changes for the better, and whose damages related to mechanical ventilation pressure have been controlled, the ECMO assistance may be removed. It is not recommended to keep ECMO intubation.
1190 十一. XI.
1191 COVID-19康复者恢复期血浆治疗 Convalescent Plasma Therapy for COVID-19 Patients
1192 自从1891年Behring及Kitasato报道白喉抗毒素血浆具有治疗效果以来,已成为急性传染病治疗的一项重要的病原体免疫治疗手段。 Since Behring and Kitasato reported the therapeutic effect s of diphtheria antitoxin plasma in 1891, plasma therapy has become an important means of pathogen immunotherapy for acute infectious diseases.
1193 新发突发传染病重症和危重症患者病情迅速进展 The disease progression is rapid for severe and critically ill patients of an emerging infectious disease.
1194 起病早期存在病原体直接损伤靶器官,进而诱导严重的免疫病理损伤,被动免疫抗体能够高效、直接中和病原体,减少靶器官损害进而阻断随后的免疫病理损伤。 In the early phase, the pathogens damage the target organs directly and then lead to severe immuno-pathological damage. The passive immune antibodies can effectively and directly neutralize the pathogens, which reduces the damage of the target organs and then block the subsequent immune-pathological damages.
1195 WHO在多次全球重大疫情爆发期间亦曾强调“恢复期血浆位于潜在疗法列表的前端,并且曾被用于其他疾病的暴发中”。 During multiple global pandemic outbreaks, WHO also emphasized that “convalescent plasma therapy is one of the most recommended potential therapies, and it has been used during other epidemic outbreaks”.
1196 2019年新型冠状病毒(COVID-19)肺炎爆发以来,由于无特效治疗手段,初期病死率较高,全社会高度关注疫情,能有效降低其危重症病死率的临床治疗手段是避免民众发生恐慌的关键。 Since the outbreak of COVID-19, the initial mortality rate was rather high due to the lack of specific and effective treatment s. As mortality rate is an important metric that the public concerns, clinic treatment s which can reduce the fatality rate of critical cases effectively are key to avoid public panic.